(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Compass Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast CMPX's revenue for 2026 to be $2,146,420,934, with the lowest CMPX revenue forecast at $525,473,492, and the highest CMPX revenue forecast at $5,437,267,821. On average, 7 Wall Street analysts forecast CMPX's revenue for 2027 to be $10,238,021,304, with the lowest CMPX revenue forecast at $4,245,272,689, and the highest CMPX revenue forecast at $23,620,033,483.
In 2028, CMPX is forecast to generate $29,527,600,080 in revenue, with the lowest revenue forecast at $16,842,808,256 and the highest revenue forecast at $45,052,437,848.